Interview: Luis Almeida, CEO, Luzitin, Portugal
Luis Almeida, CEO of Luzitin Portugal, talks about the Innovation of the Decade award Luzitin received for its patented technology, what exactly is so unique and innovative about this technology,…
Luzitin, S.A. is an early-stage pharmaceutical company focused on investigating and developing innovative compounds to be used in Photodynamic Therapy (PDT) or Photodiagnosis (PDx) of cancer or other diseases, thus contributing to the human wellness.
Luzitin emerged as a spin-off company from an R&D partnership between Bluepharma, S.A. and the University of Coimbra, Portugal. The Luzitin’s starting intellectual property is a series of new photosensitizing drugs licensed-in from the University of Coimbra. In March 2011, these new photosensitizers have been awarded the INVENTA Prize, which honoured the most relevant Portuguese invention of the 2001-2010 decade.
Luzitin’s shareholders are Bluepharma, S.A., a venture capital firm (Portugal Ventures, S.A.), and the inventors of the patented drugs. Luzitin’s headquarters are located at S Martinho do Bispo, Coimbra, Portugal. Luis Almeida, MD, PhD (Chief Executive Officer), Luis Arnaut, PhD (Chief Scientific Officer), and Sérgio Simões, PharmD, PhD (Chairman), compose the Management Team (MT). All have over 20 years of experience in their fields, and altogether they cover all disciplines involved in drug R&D from bench to bedside.
Luzitin’s long-term goal is to become a leader in PDT or PDx of cancer and other selected indications by providing innovative products and services, and partnering with other companies and public research institutions to bring new products to market.
Luzitin is committed to reach proof-of-concept clinical trials (phase II) and afterwards to negotiate licensing terms with a pharmaceutical company to further co-develop and co-market its compounds.
Contact:
Luzitin, SA
Edifício Bluepharma – Rua da Bayer – S. Martinho do Bispo
3045-016 Coimbra
PORTUGAL
Phone: +351 239 800 300
Fax: +351 239 800 333
www.luzitin.pt
Luis Almeida, CEO of Luzitin Portugal, talks about the Innovation of the Decade award Luzitin received for its patented technology, what exactly is so unique and innovative about this technology,…
P-BIO, Portugal’s leading association for its biotech industry, is approaching a quarter century in existence. Its president, Simão Soares, tells PharmaBoardroom that there has been “substantial positive change” in the…
One of Europe’s smaller nations and its westernmost, Portugal, with a pharma market worth roughly USD 3.5 billion, may not be known as the continent’s pharma powerhouse. Yet the country…
Organon’s general manager for Spain and Portugal, Juan Vera, explains the challenges of executing the spinoff from MSD in the middle of the pandemic, the reasons why his affiliate has…
Lawyer Joana Silveira Botelho provides regular legal assistance to pharmaceutical companies and other entities of the health sector. Here she examines Portugal’s new regulatory framework on cannabis for medicinal purposes. …
Santiago Ruiz, entering his fourth year leading B. Braun’s Portuguese affiliate in Lisbon, highlights the innovation present in Portugal, B. Braun’s Vision 2020 and emerging trends in the medtech world.…
Joaquim Chaves, CEO of Basi Laboratories, presents the Basi production success story to readers. Located in Mortágua, two hours north of Portugal’s third city, Coimbra, the vast production site recently…
Francisco del Val, recently nominated general manager of the business unit Sanofi Genzyme and country head of Sanofi Portugal, has two decades’ experience in the pharma industry. In his first…
Virgilio Bento, known as ‘V’ amongst his peers, invites readers to discover SWORD Health, an interactive solution for patients undergoing physical recovery programs. In this exclusive interview, he describes how…
Portugal has forged a name for itself in terms of early adoption of new technology and ideas; making the country a prime destination for clinical trials as well as a…
Coimbra Genomics aims to make genetics easier. The company has developed Elsie, a digital platform that helps make better individualized clinical decisions. They have recently been recognized as the ‘second biggest…
Eurotrials is a full-service contract research organization (CRO) with an international footprint in over five territories worlwide. Following the trend of big pharma, Eurotrials recently merged with CTI, an American…
Health Market Research (HMR) is a multinational healthcare knowledge generation company, with origins in Portugal that is making waves on the Iberian Peninsula. Since its founded in 2009 and now…
See our Cookie Privacy Policy Here
